{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:17:42Z","timestamp":1783498662407,"version":"3.55.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"DOI":"10.1038\/s41401-026-01857-y","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:36:12Z","timestamp":1783492572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structural basis for dual targeting of \u03bc-opioid and nociceptin\/orphanin FQ receptors by Cebranopadol"],"prefix":"10.1038","author":[{"given":"Ya-li","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-yi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Eric","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"1857_CR1","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","volume":"76","author":"ND Volkow","year":"2019","unstructured":"Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry. 2019;76:208\u201316.","journal-title":"JAMA Psychiatry"},{"key":"1857_CR2","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/j.1476-5381.2011.01335.x","volume":"164","author":"MM Morgan","year":"2011","unstructured":"Morgan MM, Christie MJ. Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human. Br J Pharmacol. 2011;164:1322\u201334.","journal-title":"Br J Pharmacol"},{"key":"1857_CR3","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1001\/jama.2019.15802","volume":"322","author":"E Wood","year":"2019","unstructured":"Wood E, Simel DL, Klimas J. Pain management with opioids in 2019-2020. JAMA. 2019;322:1912\u20133.","journal-title":"JAMA"},{"key":"1857_CR4","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3389\/fphar.2018.01388","volume":"9","author":"H Machelska","year":"2018","unstructured":"Machelska H, Celik M. Advances in achieving opioid analgesia without side effects. Front Pharmacol. 2018;9:1388.","journal-title":"Front Pharmacol"},{"key":"1857_CR5","doi-asserted-by":"publisher","first-page":"106966","DOI":"10.1016\/j.phrs.2023.106966","volume":"197","author":"KJ Rehrauer","year":"2023","unstructured":"Rehrauer KJ, Cunningham CW. IUPHAR review - bivalent and bifunctional opioid receptor ligands as novel analgesics. Pharmacol Res. 2023;197:106966.","journal-title":"Pharmacol Res"},{"key":"1857_CR6","doi-asserted-by":"publisher","first-page":"8019","DOI":"10.1021\/jm4010829","volume":"56","author":"XT Chen","year":"2013","unstructured":"Chen XT, Pitis P, Liu G, Yuan C, Gotchev D, Cowan CL, et al. Structure-activity relationships and discovery of a G protein biased \u03bc opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain. J Med Chem. 2013;56:8019\u201331.","journal-title":"J Med Chem"},{"key":"1857_CR7","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1124\/jpet.112.201616","volume":"344","author":"SM DeWire","year":"2013","unstructured":"DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, et al. A G protein-biased ligand at the \u03bc-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013;344:708\u201317.","journal-title":"J Pharmacol Exp Ther"},{"key":"1857_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1124\/pr.114.009209","volume":"68","author":"L Toll","year":"2016","unstructured":"Toll L, Bruchas MR, Calo G, Cox BM, Zaveri NT. Nociceptin\/Orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems. Pharmacol Rev. 2016;68:419\u201357.","journal-title":"Pharmacol Rev"},{"key":"1857_CR9","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3389\/fpsyt.2018.00638","volume":"9","author":"NT Zaveri","year":"2018","unstructured":"Zaveri NT, Marquez PV, Meyer ME, Hamid A, Lutfy K. The nociceptin receptor (NOP) agonist AT-312 blocks acquisition of morphine- and cocaine-induced conditioned place preference in mice. Front Psychiatry. 2018;9:638.","journal-title":"Front Psychiatry"},{"key":"1857_CR10","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2174\/156802611795371341","volume":"11","author":"NT Zaveri","year":"2011","unstructured":"Zaveri NT. The nociceptin\/orphanin FQ receptor (NOP) as a target for drug abuse medications. Curr Top Med Chem. 2011;11:1151\u20136.","journal-title":"Curr Top Med Chem"},{"key":"1857_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40263-022-00924-2","volume":"36","author":"F Coluzzi","year":"2022","unstructured":"Coluzzi F, Rullo L, Scerpa MS, Losapio LM, Rocco M, Billeci D, et al. Current and future therapeutic options in pain management: multi-mechanistic opioids involving both MOR and NOP receptor activation. CNS Drugs. 2022;36:617\u201332.","journal-title":"CNS Drugs"},{"key":"1857_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40122-025-00794-8","volume":"15","author":"R Ciccocioppo","year":"2026","unstructured":"Ciccocioppo R, Gudin J, Argoff CE, Offidani E, Hackworth J, Fam DS, et al. The therapeutic potential of dual NMR (NOP\/MOP) agonism in pain management. Pain Ther. 2026;15:71\u201395.","journal-title":"Pain Ther"},{"key":"1857_CR13","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1111\/bph.13809","volume":"175","author":"T G\u00fcnther","year":"2018","unstructured":"G\u00fcnther T, Dasgupta P, Mann A, Miess E, Kliewer A, Fritzwanker S, et al. Targeting multiple opioid receptors - improved analgesics with reduced side effects? Br J Pharmacol. 2018;175:2857\u201368.","journal-title":"Br J Pharmacol"},{"key":"1857_CR14","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1111\/bph.12744","volume":"171","author":"W Schr\u00f6der","year":"2014","unstructured":"Schr\u00f6der W, Lambert DG, Ko MC, Koch T. Functional plasticity of the N\/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists. Br J Pharmacol. 2014;171:3777\u2013800.","journal-title":"Br J Pharmacol"},{"key":"1857_CR15","doi-asserted-by":"publisher","first-page":"eaar3483","DOI":"10.1126\/scitranslmed.aar3483","volume":"10","author":"H Ding","year":"2018","unstructured":"Ding H, Kiguchi N, Yasuda D, Daga PR, Polgar WE, Lu JJ, et al. A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates. Sci Transl Med. 2018;10:eaar3483.","journal-title":"Sci Transl Med"},{"key":"1857_CR16","doi-asserted-by":"publisher","first-page":"E5511","DOI":"10.1073\/pnas.1605295113","volume":"113","author":"H Ding","year":"2016","unstructured":"Ding H, Czoty PW, Kiguchi N, Cami-Kobeci G, Sukhtankar DD, Nader MA, et al. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates. Proc Natl Acad Sci USA. 2016;113:E5511\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1857_CR17","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/j.bja.2018.10.065","volume":"122","author":"N Kiguchi","year":"2019","unstructured":"Kiguchi N, Ding H, Cami-Kobeci G, Sukhtankar DD, Czoty PW, DeLoid HB, et al. BU10038 as a safe opioid analgesic with fewer side effects after systemic and intrathecal administration in primates. Br J Anaesth. 2019;122:e146\u2013e56.","journal-title":"Br J Anaesth"},{"key":"1857_CR18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40265-023-01878-5","volume":"83","author":"H Ding","year":"2023","unstructured":"Ding H, Kiguchi N, Dobbins M, Romero-Sandoval EA, Kishioka S, Ko MC. Nociceptin receptor-related agonists as safe and non-addictive analgesics. Drugs. 2023;83:771\u201393.","journal-title":"Drugs"},{"key":"1857_CR19","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1021\/ml500117c","volume":"5","author":"S Schunk","year":"2014","unstructured":"Schunk S, Linz K, Hinze C, Frormann S, Oberb\u00f6rsch S, Sundermann B, et al. Discovery of a potent analgesic NOP and opioid receptor agonist: cebranopadol. ACS Med Chem Lett. 2014;5:857\u201362.","journal-title":"ACS Med Chem Lett"},{"key":"1857_CR20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1124\/jpet.114.213694","volume":"349","author":"K Linz","year":"2014","unstructured":"Linz K, Christoph T, Tzschentke TM, Koch T, Schiene K, Gautrois M, et al. Cebranopadol: a novel potent analgesic nociceptin\/orphanin FQ peptide and opioid receptor agonist. J Pharmacol Exp Ther. 2014;349:535\u201348.","journal-title":"J Pharmacol Exp Ther"},{"key":"1857_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.247","volume":"4","author":"A Rizzi","year":"2016","unstructured":"Rizzi A, Cerlesi MC, Ruzza C, Malfacini D, Ferrari F, Bianco S, et al. Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin\/orphanin FQ and opioid receptor agonist. Pharmacol Res Perspect. 2016;4:e00247.","journal-title":"Pharmacol Res Perspect"},{"key":"1857_CR22","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/FBP.0000000000000420","volume":"30","author":"K Schiene","year":"2019","unstructured":"Schiene K, Schr\u00f6der W, Linz K, Frosch S, Tzschentke TM, Christoph T, et al. Inhibition of experimental visceral pain in rodents by cebranopadol. Behav Pharmacol. 2019;30:320\u20136.","journal-title":"Behav Pharmacol"},{"key":"1857_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejphar.2018.05.005","volume":"832","author":"K Schiene","year":"2018","unstructured":"Schiene K, Schr\u00f6der W, Linz K, Frosch S, Tzschentke TM, Jansen U, et al. Nociceptin\/orphanin FQ opioid peptide (NOP) receptor and \u00b5-opioid peptide (MOP) receptors both contribute to the anti-hypersensitive effect of cebranopadol in a rat model of arthritic pain. Eur J Pharmacol. 2018;832:90\u20135.","journal-title":"Eur J Pharmacol"},{"key":"1857_CR24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1517\/13543784.2015.1036985","volume":"24","author":"K Salat","year":"2015","unstructured":"Salat K, Jakubowska A, Kulig K. Cebranopadol : a first-in-class potent analgesic agent with agonistic activity at nociceptin\/orphanin FQ and opioid receptors. Expert Opin Investig Drugs. 2015;24:837\u201344.","journal-title":"Expert Opin Investig Drugs"},{"key":"1857_CR25","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/papr.12558","volume":"17","author":"TM Tzschentke","year":"2017","unstructured":"Tzschentke TM, Linz K, Frosch S, Christoph T. Antihyperalgesic, antiallodynic, and antinociceptive effects of cebranopadol, a novel potent nociceptin\/orphanin FQ and opioid receptor agonist, after peripheral and central administration in rodent models of neuropathic pain. Pain Pract. 2017;17:1032\u201341.","journal-title":"Pain Pract"},{"key":"1857_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10787-017-0405-5","volume":"26","author":"K Salat","year":"2018","unstructured":"Salat K, Furgala A, Salat R. Evaluation of cebranopadol, a dually acting nociceptin\/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain. Inflammopharmacology. 2018;26:361\u201374.","journal-title":"Inflammopharmacology"},{"key":"1857_CR27","doi-asserted-by":"publisher","first-page":"e00444","DOI":"10.1002\/prp2.444","volume":"6","author":"T Christoph","year":"2018","unstructured":"Christoph T, Raffa R, De Vry J, Schr\u00f6der W. Synergistic interaction between the agonism of cebranopadol at nociceptin\/orphanin FQ and classical opioid receptors in the rat spinal nerve ligation model. Pharmacol Res Perspect. 2018;6:e00444.","journal-title":"Pharmacol Res Perspect"},{"key":"1857_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/164_2019_206","volume":"254","author":"TM Tzschentke","year":"2019","unstructured":"Tzschentke TM, Linz K, Koch T, Christoph T. Cebranopadol: a novel first-in-class potent analgesic acting via NOP and opioid receptors. Handb Exp Pharmacol. 2019;254:367\u201398.","journal-title":"Handb Exp Pharmacol"},{"key":"1857_CR29","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/ALN.0000000000001530","volume":"126","author":"K Linz","year":"2017","unstructured":"Linz K, Schr\u00f6der W, Frosch S, Christoph T. Opioid-type respiratory depressant side effects of cebranopadol in rats are limited by its nociceptin\/orphanin FQ peptide receptor agonist activity. Anesthesiology. 2017;126:708\u201315.","journal-title":"Anesthesiology"},{"key":"1857_CR30","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/ALN.0000000000003848","volume":"135","author":"H Ding","year":"2021","unstructured":"Ding H, Trapella C, Kiguchi N, Hsu FC, Cal\u00f3 G, Ko MC. Functional profile of systemic and intrathecal cebranopadol in nonhuman primates. Anesthesiology. 2021;135:482\u201393.","journal-title":"Anesthesiology"},{"key":"1857_CR31","doi-asserted-by":"publisher","first-page":"E193","DOI":"10.36076\/ppj.2018.3.E193","volume":"21","author":"A Scholz","year":"2018","unstructured":"Scholz A, Bothmer J, Kok M, Hoschen K, Daniels S. Cebranopadol: a novel, first-in-class, strong analgesic: results from a randomized phase iia clinical trial in postoperative acute pain. Pain Physician. 2018;21:E193\u2013e206.","journal-title":"Pain Physician"},{"key":"1857_CR32","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/ALN.0000000000001529","volume":"126","author":"A Dahan","year":"2017","unstructured":"Dahan A, Boom M, Sarton E, Hay J, Groeneveld GJ, Neukirchen M, et al. Respiratory effects of the nociceptin\/orphanin FQ peptide and opioid receptor agonist, cebranopadol, in healthy human volunteers. Anesthesiology. 2017;126:697\u2013707.","journal-title":"Anesthesiology"},{"key":"1857_CR33","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1097\/j.pain.0000000000000986","volume":"158","author":"A Christoph","year":"2017","unstructured":"Christoph A, Eerdekens MH, Kok M, Volkers G, Freynhagen R. Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial. Pain. 2017;158:1813\u201324.","journal-title":"Pain"},{"key":"1857_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40262-017-0545-1","volume":"57","author":"E Kleideiter","year":"2018","unstructured":"Kleideiter E, Piana C, Wang S, Nemeth R, Gautrois M. Clinical pharmacokinetic characteristics of cebranopadol, a novel first-in-class analgesic. Clin Pharmacokinet. 2018;57:31\u201350.","journal-title":"Clin Pharmacokinet"},{"key":"1857_CR35","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ejp.1331","volume":"23","author":"MH Eerdekens","year":"2019","unstructured":"Eerdekens MH, Kapanadze S, Koch ED, Kralidis G, Volkers G, Ahmedzai SH, et al. Cancer-related chronic pain: Investigation of the novel analgesic drug candidate cebranopadol in a randomized, double-blind, noninferiority trial. Eur J Pain. 2019;23:577\u201388.","journal-title":"Eur J Pain"},{"key":"1857_CR36","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jpainsymman.2019.05.012","volume":"58","author":"ED Koch","year":"2019","unstructured":"Koch ED, Kapanadze S, Eerdekens MH, Kralidis G, L\u00e9tal J, Sabatschus I, et al. Cebranopadol, a novel first-in-class analgesic drug candidate: first experience with cancer-related pain for up to 26 weeks. J Pain Symptom Manag. 2019;58:390\u20139.","journal-title":"J Pain Symptom Manag"},{"key":"1857_CR37","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s11916-023-01148-9","volume":"27","author":"AN Edinoff","year":"2023","unstructured":"Edinoff AN, Flanagan CJ, Roberts LT, Dies RM, Kataria S, Jackson ED, et al. Cebranopadol for the treatment of chronic pain. Curr Pain Headache Rep. 2023;27:615\u201322.","journal-title":"Curr Pain Headache Rep"},{"key":"1857_CR38","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature10954","volume":"485","author":"A Manglik","year":"2012","unstructured":"Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, Sunahara RK, et al. Crystal structure of the \u00b5-opioid receptor bound to a morphinan antagonist. Nature. 2012;485:321\u20136.","journal-title":"Nature"},{"key":"1857_CR39","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature11111","volume":"485","author":"S Granier","year":"2012","unstructured":"Granier S, Manglik A, Kruse AC, Kobilka TS, Thian FS, Weis WI, et al. Structure of the \u03b4-opioid receptor bound to naltrindole. Nature. 2012;485:400\u20134.","journal-title":"Nature"},{"key":"1857_CR40","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature10939","volume":"485","author":"H Wu","year":"2012","unstructured":"Wu H, Wacker D, Mileni M, Katritch V, Han GW, Vardy E, et al. Structure of the human \u03ba-opioid receptor in complex with JDTic. Nature. 2012;485:327\u201332.","journal-title":"Nature"},{"key":"1857_CR41","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nature11085","volume":"485","author":"AA Thompson","year":"2012","unstructured":"Thompson AA, Liu W, Chun E, Katritch V, Wu H, Vardy E, et al. Structure of the nociceptin\/orphanin FQ receptor in complex with a peptide mimetic. Nature. 2012;485:395\u20139.","journal-title":"Nature"},{"key":"1857_CR42","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cell.2022.12.026","volume":"186","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhuang Y, DiBerto JF, Zhou XE, Schmitz GP, Yuan Q, et al. Structures of the entire human opioid receptor family. Cell. 2023;186:413\u201327.","journal-title":"Cell"},{"key":"1857_CR43","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1016\/j.cell.2022.09.041","volume":"185","author":"Y Zhuang","year":"2022","unstructured":"Zhuang Y, Wang Y, He B, He X, Zhou XE, Guo S, et al. Molecular recognition of morphine and fentanyl by the human \u03bc-opioid receptor. Cell. 2022;185:4361\u201375.","journal-title":"Cell"},{"key":"1857_CR44","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1038\/aps.2016.69","volume":"37","author":"P Liu","year":"2016","unstructured":"Liu P, Jia MZ, Zhou XE, De Waal PW, Dickson BM, Liu B, et al. The structural basis of the dominant negative phenotype of the G\u03b1i1\u03b21\u03b32 G203A\/A326S heterotrimer. Acta Pharmacol Sin. 2016;37:1259\u201372.","journal-title":"Acta Pharmacol Sin"},{"key":"1857_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06002-w","volume":"9","author":"S Maeda","year":"2018","unstructured":"Maeda S, Koehl A, Matile H, Hu H, Hilger D, Schertler GFX, et al. Development of an antibody fragment that stabilizes GPCR\/G-protein complexes. Nat Commun. 2018;9:3712.","journal-title":"Nat Commun"},{"key":"1857_CR46","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nmeth.4193","volume":"14","author":"SQ Zheng","year":"2017","unstructured":"Zheng SQ, Palovcak E, Armache JP, Verba KA, Cheng Y, Agard DA. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat Methods. 2017;14:331\u20132.","journal-title":"Nat Methods"},{"key":"1857_CR47","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods. 2017;14:290\u20136.","journal-title":"Nat Methods"},{"key":"1857_CR48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 2021;30:70\u201382.","journal-title":"Protein Sci"},{"key":"1857_CR49","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams PD, Afonine PV, Bunk\u00f3czi G, Chen VB, Davis IW, Echols N, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66:213\u201321.","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"1857_CR50","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60:2126\u201332.","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"1857_CR51","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1021\/acs.jcim.9b00269","volume":"59","author":"S Schott-Verdugo","year":"2019","unstructured":"Schott-Verdugo S, Gohlke H. PACKMOL-Memgen: a simple-to-use, generalized workflow for membrane-protein-lipid-bilayer system building. J Chem Inf Model. 2019;59:2522\u20138.","journal-title":"J Chem Inf Model"},{"key":"1857_CR52","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1021\/ct100578z","volume":"7","author":"MH Olsson","year":"2011","unstructured":"Olsson MH, S\u00f8ndergaard CR, Rostkowski M, Jensen JH. PROPKA3: consistent treatment of internal and surface residues in empirical pka predictions. J Chem Theory Comput. 2011;7:525\u201337.","journal-title":"J Chem Theory Comput"},{"key":"1857_CR53","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1021\/acs.jctc.1c01217","volume":"18","author":"CJ Dickson","year":"2022","unstructured":"Dickson CJ, Walker RC, Gould IR. Lipid21: complex lipid membrane simulations with AMBER. J Chem Theory Comput. 2022;18:1726\u201336.","journal-title":"J Chem Theory Comput"},{"key":"1857_CR54","doi-asserted-by":"publisher","first-page":"114502","DOI":"10.1063\/5.0019056","volume":"153","author":"X He","year":"2020","unstructured":"He X, Man VH, Yang W, Lee TS, Wang J. A fast and high-quality charge model for the next generation general AMBER force field. J Chem Phys. 2020;153:114502.","journal-title":"J Chem Phys"},{"key":"1857_CR55","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1021\/acs.jctc.9b00591","volume":"16","author":"C Tian","year":"2020","unstructured":"Tian C, Kasavajhala K, Belfon KAA, Raguette L, Huang H, Migues AN, et al. ff19SB: amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution. J Chem Theory Comput. 2020;16:528\u201352.","journal-title":"J Chem Theory Comput"},{"key":"1857_CR56","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1021\/ct400314y","volume":"9","author":"R Salomon-Ferrer","year":"2013","unstructured":"Salomon-Ferrer R, G\u00f6tz AW, Poole D, Le Grand S, Walker RC. Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh ewald. J Chem Theory Comput. 2013;9:3878\u201388.","journal-title":"J Chem Theory Comput"},{"key":"1857_CR57","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1021\/acs.jctc.9b00160","volume":"15","author":"C Balusek","year":"2019","unstructured":"Balusek C, Hwang H, Lau CH, Lundquist K, Hazel A, Pavlova A, et al. Accelerating membrane simulations with hydrogen mass repartitioning. J Chem Theory Comput. 2019;15:4673\u201386.","journal-title":"J Chem Theory Comput"},{"key":"1857_CR58","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1021\/ct400341p","volume":"9","author":"DR Roe","year":"2013","unstructured":"Roe DR, Cheatham TE 3rd. PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput. 2013;9:3084\u201395.","journal-title":"J Chem Theory Comput"},{"key":"1857_CR59","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13321-021-00548-6","volume":"13","author":"C Bouysset","year":"2021","unstructured":"Bouysset C, Fiorucci S. ProLIF: a library to encode molecular interactions as fingerprints. J Cheminform. 2021;13:72.","journal-title":"J Cheminform"},{"key":"1857_CR60","unstructured":"Ballesteros JA, Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. In: Sealfon SC, edited. Methods in Neurosciences. San Diego: Academic Press; 1995. Vol. 25, p366\u2013428."}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01857-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01857-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01857-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:02:14Z","timestamp":1783497734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01857-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":60,"alternative-id":["1857"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01857-y","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prof H.\u00a0Eric Xu is one of the\u00a0associate editors\u00a0of Acta Pharmacologica Sinica, but he\u00a0has not been involved in the peer-review or decision-making process for this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}